BidaskClub cut shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a sell rating to a strong sell rating in a research report sent to investors on Wednesday morning, BidAskClub reports.

Several other analysts have also recently commented on the stock. HC Wainwright set a $13.00 price objective on shares of Ironwood Pharmaceuticals and gave the company a hold rating in a research note on Monday, June 24th. Wedbush raised their price objective on shares of Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the company a neutral rating in a research note on Wednesday, July 31st. Morgan Stanley set a $13.00 price objective on shares of Ironwood Pharmaceuticals and gave the company a hold rating in a research note on Friday, May 3rd. Mizuho set a $20.00 price objective on shares of Ironwood Pharmaceuticals and gave the company a buy rating in a research note on Thursday, May 2nd. Finally, ValuEngine upgraded shares of Ironwood Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $15.15.

Shares of NASDAQ IRWD opened at $8.72 on Wednesday. Ironwood Pharmaceuticals has a 52 week low of $8.69 and a 52 week high of $19.64. The firm has a 50-day moving average price of $10.03 and a 200 day moving average price of $11.68.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.15. The company had revenue of $102.22 million during the quarter, compared to analyst estimates of $89.28 million. During the same quarter last year, the business earned ($0.22) EPS. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. As a group, research analysts anticipate that Ironwood Pharmaceuticals will post 0.01 EPS for the current fiscal year.

In other Ironwood Pharmaceuticals news, insider Halley E. Gilbert sold 20,000 shares of Ironwood Pharmaceuticals stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $10.00, for a total transaction of $200,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 21,712 shares of company stock valued at $218,806. 5.90% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Marshall Wace North America L.P. acquired a new position in Ironwood Pharmaceuticals during the first quarter worth about $799,000. Norges Bank acquired a new position in Ironwood Pharmaceuticals during the fourth quarter worth about $19,568,000. Peregrine Capital Management LLC acquired a new position in Ironwood Pharmaceuticals during the second quarter worth about $13,487,000. Perennial Advisors LLC acquired a new position in Ironwood Pharmaceuticals during the first quarter worth about $243,000. Finally, Geode Capital Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 6.0% during the fourth quarter. Geode Capital Management LLC now owns 1,658,754 shares of the biotechnology company’s stock worth $17,184,000 after buying an additional 94,453 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Featured Article: What are retained earnings?

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.